
MMSI Stock Forecast & Price Target
MMSI Analyst Ratings
Bulls say
Merit Medical Systems Inc. demonstrated strong financial performance, with an operating margin increase of 300 basis points year-over-year, driven by a notable 310 basis point expansion in gross margins. The company's Cardiovascular segment achieved a revenue growth of 7.8%, supported by robust sales in cardiac intervention and a remarkable 28% increase in Delivery Systems revenue, while Endoscopy sales surged 88.1%, reflecting both organic growth and recent acquisitions. Overall, the total revenue rose by 9.4% as reported, indicating positive momentum across its product lines and a favorable macroeconomic backdrop.
Bears say
Merit Medical Systems Inc. faces significant challenges that contribute to a negative outlook on its stock, primarily stemming from disappointing earnings guidance for FY/25, which was below market expectations. The company is projected to experience revenue growth of 5% or lower, largely due to underperformance from recent acquisitions and unsuccessful new product launches, leading to further contraction in operating margins. Additionally, with an estimated dilutive impact of approximately $0.11 on non-GAAP EPS in 2025 and concerns regarding margin performance and free cash flow, the financial stability of the firm appears increasingly precarious.
This aggregate rating is based on analysts' research of Merit Medical Systems and is not a guaranteed prediction by Public.com or investment advice.
MMSI Analyst Forecast & Price Prediction
Start investing in MMSI
Order type
Buy in
Order amount
Est. shares
0 shares